Abstracts tagged "Patient reported outcomes"

Abstract Number: 2196 • ACR Convergence 2023
Females with Axial Spondyloarthritis Report Higher Burden of Disease and Worse Patient-reported Outcomes. Results from the International Map of Axial Spondyloarthritis (IMAS)
Victoria Navarro-Compán¹, Marco Garrido-Cumbrera², Denis Poddubnyy³, Christine Bundy⁴, Souzi Makri⁵, Jose Correa Fernandez⁶, Shashank Murlidhar Akerkar⁷, Lillann Wermskog⁸, Elie Karam⁹, Asif Siddiqui¹⁰ and Fernando Sommerfleck¹¹, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²University of Seville, Sevilla, Spain, ³Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁴Cardiff University, Cardiff, United Kingdom, ⁵Cyprus League for People with Rheumatism (CYLPER), Nicosia, Cyprus, ⁶Universidad de Sevilla, Health & Territory Research (HTR), Sevilla, Spain, ⁷Mumbai Arthritis Clinic, Mumbai, India, ⁸Spondyloarthritis Association of Norwary (SPAFO);Axial Spondyloarthritis International Federation (ASIF), Oslo, Norway, ⁹Canadian Spondylitis Association (CSA), Toronto, ON, Canada, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Sanatorio Julio Mendez, Buenos Aires, Argentina
Background/Purpose: There is increasing evidence of differences between males and females in axial spondyloarthritis (axSpA), but the source is restricted to specific geographic locations or…
Abstract Number: 2500 • ACR Convergence 2023
Suicidal Ideation and Self-Efficacy in Systemic Lupus Erythematosus: Georgians Organized Against Lupus (GOAL) Cohort
Charmayne Dunlop-Thomas¹, Gaobin Bao¹, Jessica Williams², Hilton Mozee¹, Cristina Drenkard¹ and S. Sam Lim¹, ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: Suicidal ideation is more common in SLE than in other chronic diseases. Targeted interventions are needed to reduce morbidity and mortality. Bandura’s theory of…
Abstract Number: 0368 • ACR Convergence 2023
Surveying Psychological Resilience and Pain in a Cross-Section of JIA Patients
Daniella Schocken and Tracy Ting, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Pain trajectories vary in JIA, with some patients developing chronic pain over the course of their illness. Adaptation and recovery under stressful or traumatic…
Abstract Number: 0521 • ACR Convergence 2023
Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies
Martin Rudwaleit¹, Victoria Navarro-Compán², Atul Deodhar³, Maureen Dubreuil⁴, Michael Frank Mørup⁵, Vanessa Taieb⁶, Christine de la Loge⁷, Carmen Fleurinck⁸, Ute Massow⁹, Thomas Vaux¹⁰ and Annelies Boonen¹¹, ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ⁴Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁵UCB Pharma, Copenhagen, Denmark, ⁶UCB Pharma, Colombes, France, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Oosterzele, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Slough, United Kingdom, ¹¹Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands
Background/Purpose: The clinical manifestations of axial spondyloarthritis (axSpA) limit physical function and work productivity, posing an economic burden to patients (pts) and society.1 Bimekizumab (BKZ),…
Abstract Number: 1108 • ACR Convergence 2023
Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout
Brian LaMoreaux¹, Chelsea McKibbon², Katie Obermeyer¹, Lissa Padnick-Silver¹, Gerald Smith², Jiaxuan Wang² and Haridarshan Patel¹, ¹Horizon Therapeutics, Deerfield, IL, ²Cytel Inc., Vancouver, BC, Canada
Background/Purpose: Gout is an inflammatory arthritis that results in severe joint inflammation, pain, disability, and lower quality of life (QoL). Determining minimal clinically important differences…
Abstract Number: 1294 • ACR Convergence 2023
Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: Using Rasch Measurement Theory and Cognitive Interviewing to Achieve More Meaningful Measurement
Tim Pickles¹, Mike Horton², Karl Bang Christensen³, Rhiannon Phillips⁴, David Gillespie¹, Neil Mo⁵ and Ernest Choy⁶, ¹Cardiff University, Cardiff, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University of Copenhagen, Copenhagen, Denmark, ⁴Cardiff Metropolitan University, Cardiff, United Kingdom, ⁵Swansea Bay University Health Board, Port Talbot, United Kingdom, ⁶Section of Rheumatology, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Disease Activity (DA) monitoring is a standard of care in Rheumatoid Arthritis (RA). A systematic review of Patient Reported Outcome Measures (PROMs) for RA…
Abstract Number: 1428 • ACR Convergence 2023
Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)
Laure Gossec¹, Xenofon Baraliakos², James Galloway³, Lars Erik⁴, Vilija Oke⁵, Petros Sfikakis⁶, Emmanouil Rampakakis⁷, Mohamed Sharaf⁸, Frederic Lavie⁹ and Iain McInnes¹⁰, ¹Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³King's College London, London, United Kingdom, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶National Kapodistrian University of Athens Medical School, Athens, Greece, ⁷JSS Medical Research, Saint-Laurent, QC, Canada, ⁸Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ¹⁰University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In the Phase 3b COSMOS trial, guselkumab (GUS), a fully human IL-23p19 inhibitor (i), was associated with significantly greater improvements vs placebo (PBO) in…
Abstract Number: 2024 • ACR Convergence 2023
Patient-Reported Outcomes in Patients with Lupus Nephritis: A Post Hoc Analysis of Control Arm Data from Two Completed Phase III Randomized Clinical Trials
Christophe T. Tchakoute¹, Huiyan (Ashley) Mao², Gene Wallenstein¹, Jorge Ross Terres¹, Seitaro Yoshida¹ and Lisa Lindsay¹, ¹Genentech, Inc., South San Francisco, CA, ²Hoffmann-La Roche Ltd, Mississauga, ON, Canada
Background/Purpose: Lupus nephritis (LN) is a severe and common (50%) organ-threatening manifestation of systemic lupus erythematosus and is associated with a high risk of progression…
Abstract Number: 2197 • ACR Convergence 2023
Diagnostic Delay in Patients Included in the International Map of Axial Spondyloarthrtis: Associations with Geographic, Socio-demographic and Disease-related Factors
Denis Poddubnyy¹, Marco Garrido-Cumbrera², Fernando Sommerfleck³, Victoria Navarro-Compán⁴, Christine Bundy⁵, Souzi Makri⁶, Jose Correa Fernandez⁷, Shashank Murlidhar Akerkar⁸, Jo Davies⁹, Laura Christen¹⁰ and Elie Karam¹¹, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²University of Seville, Sevilla, Spain, ³Sanatorio Julio Mendez, Buenos Aires, Argentina, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵Cardiff University, Cardiff, United Kingdom, ⁶Cyprus League for People with Rheumatism (CYLPER), Nicosia, Cyprus, ⁷Universidad de Sevilla, Health & Territory Research (HTR), Sevilla, Spain, ⁸Mumbai Arthritis Clinic, Mumbai, India, ⁹Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Canadian Spondylitis Association (CSA), Toronto, ON, Canada
Background/Purpose: Despite efforts for early detection, delayed diagnosis in axial spondyloarthritis (axSpA) remains an unresolved challenge. This analysis aimed to assess diagnostic delay and its…
Abstract Number: 2579 • ACR Convergence 2023
Validation of PROMIS in Adult and Pediatric Patients with Idiopathic Inflammatory Myopathies
Emma Austenfeld¹, Sara Sabbagh¹, Melodee Liegl¹, Ke Yan¹, Julie Fuller², Kelly Rouster-Stevens³, Lisa Rider⁴ and Adam Schiffenbauer⁴, ¹Medical College of Wisconsin, Wauwatosa, WI, ²UT Southwestern and Scottish Rite for Children, Dallas, TX, ³Emory University/Children's Healthcare of Atlanta, Norcross, GA, ⁴NIEHS, NIH, Bethesda, MD
Background/Purpose: This study aimed to validate the Patient Reported Outcome Measurement Information System (PROMIS) tools in patients with adult and juvenile idiopathic inflammatory myopathies (IIM/JIIM)…
Abstract Number: 0381 • ACR Convergence 2023
Disease Burden, Patient Experiences, and Unmet Needs in Refractory Rheumatoid Arthritis: Insights from 20 Years of Real-World Data
Kristin Wipfler¹, Bobby Kwanghoon Han², Sofia Pedro³, Urbano Sbarigia⁴, Federico Zazzetti⁵, Anna Sheahan⁶, Iris Lin⁷, Patti Katz⁸, Evo Alemao⁹ and Kaleb Michaud¹⁰, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Washington, Seattle, WA, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴Janssen Pharmaceutica, Beerse, Belgium, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen, Raleigh, NC, ⁷Janssen, Horsham, PA, ⁸University of California San Francisco, San Rafael, CA, ⁹Janssen Pharmaceuticals, New Hope, PA, ¹⁰University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Despite major advances in RA treatment, a substantial number of patients (estimated at 6-21%1) are refractory to multiple advanced therapies. Well-defined refractory RA (reRA)…
Abstract Number: 0526 • ACR Convergence 2023
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
Maureen Dubreuil¹, Karl Gaffney², Jonathan Kay³, Victoria Navarro-Compán⁴, Christine de la Loge⁵, Alicia Ellis⁶, Carmen Fleurinck⁷, Ute Massow⁸, Vanessa Taieb⁹ and Atul Deodhar¹⁰, ¹Department of Rheumatology, Boston University School of Medicine, Milton, MA, ²Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ³Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Raleigh, NC, ⁷UCB Pharma, Oosterzele, Belgium, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹UCB Pharma, Colombes, France, ¹⁰Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) severely impairs physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in…
Abstract Number: 1182 • ACR Convergence 2023
Treatment Trajectories and Patient Outcomes in Idiopathic Inflammatory Myopathies
Kristin Wipfler¹, Michael Feely², Gulsen Ozen³, Urbano Sbarigia⁴, Federico Zazzetti⁵, Anna Sheahan⁶, Iris Lin⁷, Evo Alemao⁸ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Bellevue, NE, ⁴Janssen Pharmaceutica, Beerse, Belgium, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen, Raleigh, NC, ⁷Janssen, Horsham, PA, ⁸Janssen Pharmaceuticals, New Hope, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare, heterogeneous diseases characterized by chronic skeletal muscle inflammation and weakness. Initial conventional therapy is based on expert opinion…
Abstract Number: 1295 • ACR Convergence 2023
Having More Tender Than Swollen Joints Is Associated with Worse Functional Outcomes in Patients with Early RA in a Prospective Real-World Cohort
Charis Meng¹, Yvonne Lee², Orit Schieir³, Marie-France Valois⁴, Margaret Butler¹, Gilles Boire⁵, Glen Hazelwood⁶, Carol Hitchon⁷, Edward Keystone⁸, Diane Tin⁹, Carter Thorne¹⁰, Louis Bessette¹¹, Janet Pope¹², Susan Bartlett¹³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²Northwestern University, Chicago, IL, ³McGill University, Montréal, QC, Canada, ⁴McGill University, Pointe-Claire, QC, Canada, ⁵Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Manitoba, MB, Canada, ⁸Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁹Centre of Arthritis Excellence, Newmarket, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ¹²University of Western Ontario, London, ON, Canada, ¹³McGill University, Montreal, QC, Canada
Background/Purpose: Early RA patients may present with more tender than swollen joints, which can persist during DMARD therapy. Elevated TSJD (tender-swollen joint difference) is often…
Abstract Number: 1487 • ACR Convergence 2023
Prevalence of Objectively Measured Sleep Disturbance in Systemic Lupus Erythematosus (SLE)
Patti Katz¹, Jinoos Yazdany² and Maria Dall'Era³, ¹University of California San Francisco, San Rafael, CA, ²University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ³University of California San Francisco, San Francisco, CA
Background/Purpose: Self-reported poor sleep is common in SLE, but few studies have objectively measured sleep have been conducted. In general population studies, sleep disorders are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].